McN3716

SKU: orb1709167

Description

McN3716 is a potent and selective inhibitor of carnitine palmitoyltransferase I (CPT-1). It is a valuable research tool for investigating fatty acid oxidation in metabolic disease models, including in vitro assays and in vivo studies of obesity and type 2 diabetes.

Research Area

Metabolism Research

Key Properties

• CAS Number: 69207-52-9
• MW: 298.46
• Purity: >99.99% (May vary between batches)
• Formula: C₁₈H₃₄O₃
• SMILES: CCCCCCCCCCCCCCC1(CO1)C(=O)OC
• Target: Mitochondrial Metabolism,CPT
• Solubility: DMSO:2.99 mg/mL (10.02 mM)

Bioactivity

• In Vivo:
  Significantly reducing the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, McN3716 (Methyl palmoxirate, MEP) achieves inhibition of brain mitochondrial β-oxidation. Notably, 15-HETE remains unaffected. McN3716 treatment leads to a significant 34% reduction in the level of 6-keto-PGF1α, a byproduct of PGI2 (prostacyclin). Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to the vehicle.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Carnitine palmitoyltransferase I (CPT-1), CPT1, NSC 359682, NSC359682, NSC-359682, Methyl palmoxirate, Mitochondrial Metabolism, MitochondrialMetabolism, McN3716, McN-3716, McN 3716

Compound Identifiers

PubChem CID

68593